Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
A Single-Arm Phase II Study of Alemtuzumab in Combination With High-Dose Methylprednisolone in CLL Patients With p53 Deletion
This study is not yet open for participant recruitment.
Study NCT00292760.   Last updated on October 12, 2006.
Information provided by Royal Marsden NHS Foundation Trust
Please refer to this study by its ClinicalTrials.gov identifier: NCT00292760
Sponsors and Collaborators
Royal Marsden NHS Foundation Trust
Investigators
Principal Investigator: Andrew Pettitt Royal Liverpool University Hospital




U.S. National Library of Medicine,  Contact Help Desk
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services